We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

MYRG:NASDAQMYR Group, Inc. Analysis

Data as of 2026-05-23 - not real-time

$446.90

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

MYR Group’s stock is trading well above its short‑term moving average while remaining above the mid‑term average, underscoring a clear bullish trajectory. The long‑term trend line remains firmly below the current price, reinforcing sustained strength. Momentum indicators show an elevated RSI, indicating strong buying pressure. The MACD histogram has turned negative, hinting at a short‑term pullback, but the overall MACD line stays above the signal, supporting continued upside. Recent earnings released this quarter revealed a notable lift in gross margins and operating efficiency, driving investor enthusiasm.
Valuation metrics place the market price just modestly above the discounted cash‑flow estimate, suggesting the stock is fairly priced with limited upside. The company trades at a price‑to‑earnings multiple well above the industry average, reflecting growth expectations rather than pure value. With no dividend payout, income‑focused investors will find the stock unsuitable for yield‑oriented strategies. A beta above the market and heightened recent volatility signal heightened market sensitivity, while decreasing volume adds a modest liquidity concern. Considering the strong operational backdrop, modest valuation premium, and the technical picture, the recommendation leans toward a cautious buy stance for the near term and a hold for longer horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • technical bullish alignment
  • margin improvement news
  • price near support

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • sustained growth outlook
  • fair valuation relative to DCF
  • industry tailwinds in clean energy infrastructure

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • elevated valuation relative to peers
  • high beta and volatility
  • absence of dividend reduces yield appeal

Key Metrics & Analysis

Financial Health

Revenue Growth20.00%
Profit Margin3.71%
P/E Ratio49.3
ROE22.68%
ROA7.56%
Debt/Equity8.75
P/B Ratio9.9
Op. Cash Flow$328.0M
Free Cash Flow$227.8M
Industry P/E29.7

Technical Analysis

TrendBullish
RSI62.4
Support$329.74
Resistance$480.00
MA 20$432.13
MA 50$350.83
MA 200$254.09
MACDBearish
VolumeDecreasing
Fear & Greed Index91.61

Valuation

Fair Value$437.64
Target Price$455.00
Upside/Downside1.81%
GradeFair
TypeGrowth

Risk Assessment

Beta1.74
Volatility68.25%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.